4 ms·

I think this is only a half-truth. There certainly are examples of academic research being translated into lucrative products by industry (there are even promin

I think this is only a half-truth. There certainly are examples of academic research being translated into lucrative products by industry (there are even prominent examples in software/systems engineering) but I think that many times the translation of academic research into a useable product is also a massive endeavor that deserves recognition in its own right. I see this scenario described in medical research all the time with people saying that industry just leeches off of academic research and what people leave out conveniently is the vast amounts of money and research that goes into translating research into a real drug (billions spent on clinical trials to meet regulation, millions to billions spent on scaling manufacturing and synthesis of the drug to industrial volumes, drug delivery like pill design or injection methods) Additionally many industries also do have well-paid research positions that "move the needle" on science and basic research. While they're more targeted at producing and supporting products instead of full liberty to exploring just for the sake of knowledge, it's not like there is a complete black and white poorly compensated academic research vs industry.

photochemsyn 4y ago
Fundamental: the patents produced by taxpayer-financed academic research have no business being exclusively licensed to some pharmaceutical corporation. As far as the cost of clinical trials being borne by those companies, well, let's get the FDA involved in the clinical trials. Then the competition can come in, i.e. whoever can produce pure preparations of those drugs at the lowest cost will win the most market share. This means investing in top-of-the line manufacturing platforms (much of this is now outsourced to India, Mexico, etc. for drugs being sold in the USA) instead of squatting on the patents, blocking competition, and using monopoly status to jack up prices. Yes, this would greatly reduce the profit margins and perhaps the stock prices of Big Pharma outfits, but the overall benefits would greatly outweight this. As a practical example, look how the best Covid vaccines (mRNA types) have been monopolized, leading to low rates of vaccination in Africa etc., even though that was technology developed with taxpayer funding at public universities.
- jollybean 4y ago
  No, if a Uni has developed some patents, and wants to 'exclusively license' them to a Pharma, that's probably a good application of that patent, they become much less worthwhile otherwise. It's a misunderstanding of the market to suggest that somehow 'the FDA will lead the trials'. This is about as likely as a manned mission to Venus, it won't happen, and it shouldn't happen for good reason (cost vastly outweighs the benefits). It's also a misunderstanding to suggest 'whoever can produce pure preparations of those drugs at the lowest cost will win the most market share'. The 'cost of manufacture' is most cases is not a material or relevant issue. Your example of 'COVID' monopolization is completely upside down - companies didn't maximize their profit potential there, and may not have even developed such vaccines in a normal case, they were giving very special prices to places like 'Africa' - and none of this has anything to do with 'low uptake' in Africa. Africa has 'low uptake' for the very same set of reasons they don't have electricity, or consistent electricity in many places.
  - photochemsyn 4y ago
    Non-exclusive licensing is the far better option. This prevents monopolization and ridiculous price increases. As far as clinical trials by exclusive license holders, those have a rather poor record of producing reliable results over the long term in many cases (Vioxx of course, there are many others). The trials should really be independently run, not controlled by the very corporations that have a vested interest in seeing positive results so they can go to market. As far as Covid-19 vaccines, there are actually many companies ready to go right to production if those patents are released to the public at this moment, and that would greatly increase supply, and that would benefit the whole world, instead of a handful of pharma CEOs and affiliated shareholders.
    - kongolongo 4y ago
      >As far as Covid-19 vaccines, there are actually many companies ready to go right to production if those patents are released to the public at this moment, and that would greatly increase supply, and that would benefit the whole world, instead of a handful of pharma CEOs and affiliated shareholders. That's just conspiracy. Many companies have not been enforcing any patents related to covid vaccines. The reason why the developing world does not have high vaccine adoption is because of their infrastructure, not because of patent blocking.

photochemsyn 4y ago

Fundamental: the patents produced by taxpayer-financed academic research have no business being exclusively licensed to some pharmaceutical corporation. As far as the cost of clinical trials being borne by those companies, well, let's get the FDA involved in the clinical trials. Then the competition can come in, i.e. whoever can produce pure preparations of those drugs at the lowest cost will win the most market share. This means investing in top-of-the line manufacturing platforms (much of this is now outsourced to India, Mexico, etc. for drugs being sold in the USA) instead of squatting on the patents, blocking competition, and using monopoly status to jack up prices. Yes, this would greatly reduce the profit margins and perhaps the stock prices of Big Pharma outfits, but the overall benefits would greatly outweight this. As a practical example, look how the best Covid vaccines (mRNA types) have been monopolized, leading to low rates of vaccination in Africa etc., even though that was technology developed with taxpayer funding at public universities.

jollybean 4y ago
No, if a Uni has developed some patents, and wants to 'exclusively license' them to a Pharma, that's probably a good application of that patent, they become much less worthwhile otherwise. It's a misunderstanding of the market to suggest that somehow 'the FDA will lead the trials'. This is about as likely as a manned mission to Venus, it won't happen, and it shouldn't happen for good reason (cost vastly outweighs the benefits). It's also a misunderstanding to suggest 'whoever can produce pure preparations of those drugs at the lowest cost will win the most market share'. The 'cost of manufacture' is most cases is not a material or relevant issue. Your example of 'COVID' monopolization is completely upside down - companies didn't maximize their profit potential there, and may not have even developed such vaccines in a normal case, they were giving very special prices to places like 'Africa' - and none of this has anything to do with 'low uptake' in Africa. Africa has 'low uptake' for the very same set of reasons they don't have electricity, or consistent electricity in many places.
- photochemsyn 4y ago
  Non-exclusive licensing is the far better option. This prevents monopolization and ridiculous price increases. As far as clinical trials by exclusive license holders, those have a rather poor record of producing reliable results over the long term in many cases (Vioxx of course, there are many others). The trials should really be independently run, not controlled by the very corporations that have a vested interest in seeing positive results so they can go to market. As far as Covid-19 vaccines, there are actually many companies ready to go right to production if those patents are released to the public at this moment, and that would greatly increase supply, and that would benefit the whole world, instead of a handful of pharma CEOs and affiliated shareholders.
  - kongolongo 4y ago
    >As far as Covid-19 vaccines, there are actually many companies ready to go right to production if those patents are released to the public at this moment, and that would greatly increase supply, and that would benefit the whole world, instead of a handful of pharma CEOs and affiliated shareholders. That's just conspiracy. Many companies have not been enforcing any patents related to covid vaccines. The reason why the developing world does not have high vaccine adoption is because of their infrastructure, not because of patent blocking.